A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study

Bruton tyrosine kinase (BTK) inhibition is an effective treatment approach for patients with Waldenström macroglobulinemia (WM). The phase 3 ASPEN study compared the efficacy and safety of ibrutinib, a first-generation BTK inhibitor, with zanubrutinib, a novel highly selective BTK inhibitor, in pati...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Blood
Asıl Yazarlar: Tam, Constantine S., Opat, Stephen, D'Sa, Shirley, Jurczak, Wojciech, Lee, Hui-Peng, Cull, Gavin, Owen, Roger G., Marlton, Paula, Wahlin, Björn E., Sanz, Ramón Garcia, McCarthy, Helen, Mulligan, Stephen, Tedeschi, Alessandra, Castillo, Jorge J., Czyz, Jaroslaw, Fernández de Larrea, Carlos, Belada, David, Libby, Edward, Matous, Jeffrey V., Motta, Marina, Siddiqi, Tanya, Tani, Monica, Trneny, Marek, Minnema, Monique C., Buske, Christian, Leblond, Veronique, Trotman, Judith, Chan, Wai Y., Schneider, Jingjing, Ro, Sunhee, Cohen, Aileen, Huang, Jane, Dimopoulos, Meletios
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: American Society of Hematology 2020
Konular:
Clinical Trials and Observations
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7596850/
https://ncbi.nlm.nih.gov/pubmed/32731259
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood.2020006844
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller